| 1 |
Ion-exchange resins as drug delivery carriers
Xiaodi Guo, Rong-Kun Chang, Munir A. Hussain · Journal of Pharmaceutical Sciences
|
18 Feb 2009 |
128 |
| 2 |
New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
Chung‐Ping Yu, Jennie García‐Olivares, Shawn A. Candler et al. · Journal of Experimental Pharmacology
Open access |
Aug 2020 |
93 |
| 3 |
Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment
Alisa R. Kosheleff, Oren Mason, Rakesh Jain et al. · Journal of Attention Disorders
Open access |
6 Mar 2023 |
89 |
| 4 |
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children
Azmi F. Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics
Open access |
25 Jul 2020 |
85 |
| 5 |
A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD
Janet K. Johnson, Tesfaye Liranso, Keith E. Saylor et al. · Journal of Attention Disorders
Open access |
29 Mar 2019 |
62 |
| 6 |
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Robert L. Findling, Shawn A. Candler, Azmi F. Nasser et al. · CNS Drugs
Open access |
18 May 2021 |
55 |
| 7 |
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial
Azmi F. Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics
Open access |
6 Mar 2021 |
55 |
| 8 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
Azmi F. Nasser, Joseph T. Hull, Soumya A. Chaturvedi et al. · CNS Drugs
Open access |
27 Jul 2022 |
53 |
| 9 |
Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: a randomized controlled trial
Jacqueline A. French, Paolo Baroldi, Scott T. Brittain et al. · Acta Neurologica Scandinavica
Open access |
21 Dec 2013 |
53 |
| 10 |
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
Janani S. Iyer et al. · Nature Medicine
Open access |
7 Aug 2024 |
50 |
| 11 |
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
Azmi F. Nasser, Tesfaye Liranso, Toyin Adewole et al. · Journal of Clinical Psychopharmacology
Open access |
8 May 2021 |
44 |
| 12 |
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
Azmi F. Nasser, Tesfaye Liranso, Toyin Adewole et al. · PubMed
Open access |
16 Mar 2021 |
36 |
| 13 |
A Double-blind, Placebo-Controlled Study of the Impact of Galantamine on Anterograde Memory Impairment During Electroconvulsive Therapy
John Matthews, Caleb J. Siefert, Mark A. Blais et al. · Journal of Ect
|
22 Mar 2013 |
34 |
| 14 |
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials
Stephen V. Faraone, Roberto Goméni, Joseph T. Hull et al. · Psychiatry Research
Open access |
7 Jan 2021 |
33 |
| 15 |
Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients
Gary A. Noskin, Larry Pietrelli, Marc Gurwith et al. · Bone Marrow Transplantation
|
23 Mar 1999 |
33 |
| 16 |
Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations
Scott T. Brittain, James W. Wheless · Epilepsy & Behavior
Open access |
24 Sep 2015 |
32 |
| 17 |
Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
Shamia L. Faison, Nicholas Fry, Toyin Adewole et al. · Journal of Clinical Psychopharmacology
Open access |
12 Feb 2021 |
28 |
| 18 |
Metabolism and in vitro drug–drug interaction assessment of viloxazine
Chung‐Ping Yu · Xenobiotica
Open access |
12 May 2020 |
26 |
| 19 |
A Phase 2a Randomized, Parallel Group, Dose-Ranging Study of Molindone in Children with Attention-Deficit/Hyperactivity Disorder and Persistent, Serious Conduct Problems
Jennifer Dugan Stocks, Baldeo K. Taneja, Paolo Baroldi et al. · Journal of Child and Adolescent Psychopharmacology
|
28 Feb 2012 |
26 |
| 20 |
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients
Jürgen B. Bulitta, Ping Zhao, Robert D. Arnold et al. · Cancer Chemotherapy and Pharmacology
|
12 Sep 2008 |
26 |
| 21 |
A randomized, double‐blind, placebo‐controlled study of the kappa opioid receptor antagonist, CERC‐501, in a human laboratory model of smoking behavior
Jermaine D. Jones, Shanna L. Babalonis, Ronald N. Marcus et al. · Addiction Biology
Open access |
26 Jun 2019 |
24 |
| 22 |
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials
Azmi F. Nasser, Joseph T. Hull, Tesfaye Liranso et al. · Neuropsychiatric Disease and Treatment
Open access |
Jun 2021 |
23 |
| 23 |
Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
Shamia L. Faison, Nicholas Fry, Toyin Adewole et al. · Clinical Drug Investigation
Open access |
23 Dec 2020 |
23 |
| 24 |
Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents
Andrew J. Cutler, Gregory W. Mattingly, Rakesh Jain et al. · CNS Spectrums
Open access |
30 Oct 2020 |
23 |
| 25 |
Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
Azmi F. Nasser, Roberto Goméni, Zhao Wang et al. · The Journal of Clinical Pharmacology
Open access |
16 Jul 2021 |
22 |
| 26 |
Sustained effects of repeated levodopa (L-DOPA) administration on reward circuitry, effort-based motivation, and anhedonia in depressed patients with higher inflammation
Mandakh Bekhbat, Zhihao Li, Boadie Waid Dunlop et al. · Brain Behavior and Immunity
Open access |
16 Dec 2024 |
20 |
| 27 |
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial
Stephen V. Faraone, Roberto Goméni, Joseph T. Hull et al. · Psychiatry Research
Open access |
23 Oct 2022 |
20 |
| 28 |
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Azmi F. Nasser, Alisa R. Kosheleff, Joseph T. Hull et al. · Journal of Child and Adolescent Psychopharmacology
Open access |
18 Feb 2021 |
20 |
| 29 |
Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults
Azmi F. Nasser, Shamia L. Faison, Tesfaye Liranso et al. · The Journal of Clinical Psychiatry
Open access |
12 Oct 2020 |
19 |
| 30 |
Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study
Stuart Isaacson, Alberto J. Espay, Rajesh Pahwa et al. · Journal of Parkinson s Disease
Open access |
29 Jan 2025 |
18 |
| 31 |
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
Stephen V. Faraone, Roberto Goméni, Joseph T. Hull et al. · Pediatric Drugs
Open access |
15 Sep 2021 |
17 |
| 32 |
Use of computer simulations to test the concept of dose forgiveness in the era of extended-release (XR) drugs
John M. Pellock, Scott T. Brittain · Epilepsy & Behavior
Open access |
24 Dec 2015 |
17 |
| 33 |
Association between relative age at school and persistence of ADHD in prospective studies: an individual participant data meta-analysis
Corentin J. Gosling et al. · The Lancet Psychiatry
ReviewOpen access160 authors |
25 Oct 2023 |
16 |
| 34 |
Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults
Zhao Wang, Alisa R. Kosheleff, Lilian Adeojo et al. · Clinical Pharmacology in Drug Development
Open access |
4 May 2021 |
16 |
| 35 |
Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model
Kevin Joseph Harrington, K.N. Syrigos, Paul S. Uster et al. · British Journal of Cancer
Open access |
15 Jun 2004 |
15 |
| 36 |
Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder
Jennie García‐Olivares, Brittney Yegla, Frank P. Bymaster et al. · Journal of Experimental Pharmacology
Open access |
2024 |
12 |
| 37 |
Belatacept for maintenance immunosuppression in cardiothoracic transplantation: The potential frontier
Christopher R. Ensor, Kimberly C. Goehring, Carlo J. Iasella et al. · Clinical Transplantation
|
30 Jul 2018 |
12 |
| 38 |
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder
Azmi F. Nasser, Alisa R. Kosheleff, Joseph T. Hull et al. · International Journal of Clinical Practice
Open access |
10 May 2021 |
11 |
| 39 |
SAR genotoxicity and tumorigenicity predictions for 2-MI and 4-MI using multiple SAR software
Kavya A. Krishna, Saryu Goel, Gopala Krishna · Toxicology Mechanisms and Methods
|
8 Jan 2014 |
11 |
| 40 |
A Double-Blind, Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD
Gianpiera Ceresoli‐Borroni, Azmi F. Nasser, Toyin Adewole et al. · Journal of Attention Disorders
|
26 Apr 2020 |
10 |
| 41 |
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
Stephen V. Faraone, Roberto Goméni, Joseph T. Hull et al. · European Child & Adolescent Psychiatry
Open access |
28 Sep 2021 |
9 |
| 42 |
A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression
Adelaide S. Robb, Stefan Schwabe, Gianpiera Ceresoli‐Borroni et al. · Postgraduate Medicine
Open access |
25 Jan 2019 |
9 |
| 43 |
Toxicity assessment of molindone hydrochloride, a dopamine D2/D5 receptor antagonist in juvenile and adult rats
Gopala Krishna, Gopa Gopalakrishnan, Saryu Goel · Toxicology Mechanisms and Methods
Open access |
Feb 2017 |
9 |
| 44 |
Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree ® ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder
Stephen V. Faraone, Roberto Goméni, Joseph T. Hull et al. · Brain and Behavior
Open access |
27 Feb 2023 |
8 |
| 45 |
113 Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P303) Assessing Efficacy and Safety of Extended-Release Viloxazine in Children with ADHD
Azmi F. Nasser, Joseph T. Hull, Fatima A. Chowdhry et al. · CNS Spectrums
Open access |
Apr 2020 |
8 |
| 46 |
In vitro pharmacological characterization of SPN-810M (molindone)
Chung‐Ping Yu, Gopakumar Gopalakrishnan · Journal of Experimental Pharmacology
Open access |
Nov 2018 |
8 |
| 47 |
Long‐term efficacy and safety of adjunctive extended‐release oxcarbazepine (Oxtellar XR ® ) in adults with partial‐onset seizures
S. S. Chung, Janet K. Johnson, Scott T. Brittain et al. · Acta Neurologica Scandinavica
Open access |
6 Aug 2015 |
8 |
| 48 |
Pediatric Psychopharmacology
Robert L. Findling · The Journal of Clinical Psychiatry
Open access |
15 Sep 2012 |
8 |
| 49 |
Extended-release amantadine for OFF-related dystonia in Parkinson's disease
Alberto J. Espay, Jill L. Ostrem, Andrea E. Formella et al. · Parkinsonism & Related Disorders
Open access |
4 Mar 2024 |
7 |
| 50 |
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia
Rajesh Pahwa, Susan Helen Fox, Robert A. Hauser et al. · Frontiers in Neurology
Open access |
20 Oct 2022 |
7 |